A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 8, 2009, Pages 2859-2863

  Alonso Magdalena, Paloma ^a   Brössner, Clemens ^b   Reiner, Angelika ^c   Cheng, Guojun ^a,d   Sugiyama, Nobuhiro ^a,d   Warner, Margaret ^a,d   Gustafsson, Jan Åke ^a,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^c DANUBE HOSPITAL   (Austria)

^d University of Houston   (United States)

Author keywords

Proliferation; TGF beta signaling

Indexed keywords

ANDROGEN RECEPTOR; CELL MARKER; CYCLINE; ESTROGEN RECEPTOR BETA; HORMONE RECEPTOR; KI 67 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN;

APOPTOSIS; ARTICLE; BASAL CELL; CELL ADHESION; CELL POLARITY; CELL PROLIFERATION; CELL STRUCTURE; CELL TRANSFORMATION; CLINICAL ARTICLE; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; MESENCHYME CELL; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPINDLE CELL; STROMA CELL;

APOPTOSIS; CELL ADHESION; CELL PROLIFERATION; EPITHELIAL CELLS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESODERM; PROSTATIC HYPERPLASIA; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

GASTROPODA;

EID: 62449153891     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0812666106     Document Type: Article

References (41)

1. Riolan J (1649) in Opera Anatomica, Vetera; Recognita and Auctiora, ed Lutetiae Parisiorum, pp 874-930.
2. Rohr HP, Bartsch G (1980) Human benign prostatic hyperplasia: a stromal disease? New perspectives by quantitative morphology. Urology 16:625-633.
3. Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474-479.
4. Tiwari A, Krishna N5, Nanda K, Chugh A (2005) Benign prostatic hyperplasia: an insight into current investigational medical therapies. Expert Opin Investig Drugs 14:1359-1372.
5. Schroder FH (1994) Medical treatment of benign prostatic hyperplasia: the effect of surgical or medical castration. Prog Clin Biol Res 386:191-196.
6. Bartsch G, Rittmaster RS, Klocker H (2002) Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol 19:413-425.
7. Krieg M, Bartsch W, Janssen W, Voigt KD (1979) A comparative study of binding, metabolism and endogenous levels of androgens in normal, hyperplastic and carcinomatous human prostate. J Steroid Biochem 11:615-624.
8. Walsh PC, Hutchins GM, Ewing LL (1983) Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal. J Clin Invest 72:1772-1777.
9. McNeal JE (1978) Origin and evolution of benign prostatic enlargement, Invest Urol 15:340-345.
10. Lin VK, et al. (2007) Prostatic stromal cells derived from benign prostatic hyperplasia specimens possess stem cell like property. Prostate 67:1265-1276.
11. Kramer G, Mitteregger D, Marberger M (2007) Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51:1202-1216.
12. Feder-Mengus C, et al. (2008) High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. Eur J Cancer 44:2266-2275.
13. Kozak I, Bartsch W, Krieg M, Voigt KD (1982) Nuclei of stroma: site of highest estrogen concentration in human benign prostatic hyperplasia. Prostate 3:433-438.
14. Huang X, Lee C (2003) Regulation of stromal proliferation, growth arrest, differentiation and apoptosis in benign prostatic hyperplasia byTGF-beta. Front Biosci:8s740-749.
15. Shibata Y,et al, (2000) Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate 42:45-55.
16. Tsugaya M, et al. (1996) Testosterone metabolism in primary cultures of epithelial cells and stroma from benign prostatic hyperplasia. Urol Res 24:265-271.
17. Wu Q, et al. (2008) Regulation of proliferation and differentiation of prostatic stromal cells by oestradiol through prostatic epithelial cells in a paracrine manner. BJU Int 101:497-502.
18. Zavadil J, Bottinger EP (2005) TGF-beta and epithelial-to-mesenchyrmal transitions Oncogene 24:5764-5774.
19. evitt JM, Slawin KM (2007) Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression. Curr Urol Rep 8:269-274.
20. Claus S, Wrenger M, Senge T, Schulze H (1993) Immunohistochemical determination of age related proliferation rates in normal and benign hyperplastic human prostates Urol Res 21:305-308.
21. McNeal JE, Haillot O, Yemoto C (1995) Cell proliferation in dysplasia of the prostate: analysis by PCNA immunostaining. Prostate 27:258-268.
22. Kyprianou N, Tu H, Jacobs SC (1996) Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol 27:668-675.
23. Zhang X, Zhang Q, Zhang Z, Na Y, Guo Y (2006) Apoptosis profiles in benign prostatic hyperplasia: close associations of cell kinetics with percent area density of histologic composition. Urology 68:905-910.
24. Lee JM, Dedhar S, Kalluri R, Thompson EW (2006) The epithelial- mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172:973-981.
25. Gilles C, et al. (2003) Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res 63:2658-2664.
26. Fraga CH, True LD, Kirk D (1998) Enhanced expression of the mesenchymal marker, vimentin, in hyperplastic versus normal human prostatic epithelium. J Urol 159:270-274.
27. Mori H, et al. (1990) Increased expression of genes for basic fibroblast growth factor and transforming growth factor type beta 2 in human benign prostatic hyperplasia Prostate 16:71-80.
28. Lucia MS, Lambert JR (2008) Growth factors in benign prostatic hyperplasia: basic science implications. Curr Urol Rep 9:272-278.
29. Peehl DM, Sellers RG (1997) Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. Exp Cell Res 232:208-215.
30. Tuxhorn JA, et al. (2002) Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 8:2912-2923.
31. Massague J (2000) How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1:169-178.
32. Tsurusaki T, et al. (2003) Zone-dependent expression of estrogen receptors alpha and beta in human benign prostatic hyperplasia. J Clin Endocrinol Metab 88:1333-1340.
33. Schulze H, Claus S (1990) Histological localization of estrogen receptors in normal and diseased human prostates by immunocytochemistry. Prostate 16:331-343.
34. Fleisch MC, Maxwell CA, Barcellos-Hoff MH (2006) The pleiotropic roles of transforming growth factor beta in homeostasis and carcinogenesis of endocrine organs. Endocr Relat Cancer 13:379-400.
35. Hawse J R, et al. (2008) Estrogen receptor beta isoform-specific induction of transforming growth factor beta-inducible early gene-1 in human osteoblast cells: an essential role for the activation function 1 domain. Mol Endocrinol 22:1579-1595.
36. Moore JT, et al. (1998) Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 247:75-78.
37. Ogawa S, et al. (1998) Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res 26:3505-3512.
38. Esslimani-Sahla M, et al. (2005) Increased estrogen receptor betacx expression during mammary carcinogenesis. Clin Cancer Res 11:3170-3174.
39. Sakko AJ, et al. (2001) Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta 1 Cancer Res 61:926-930.
40. Cross NA, et al. (2005) The expression and regulation of ADAMTS-1, -4, -5, -9, and-15, and TIMP-3 by TGFbeta 1 in prostate cells: relevance to the accumulation of versican Prostate 63:269-275.
41. Read JT, et al. (2007) Androgen receptor regulation of the versican gene through an androgen response element in the proximal promoter.J Biol Chem 282:31954-31963.